Aberdeen Group plc Has $54.04 Million Stake in BioMarin Pharmaceutical Inc. $BMRN

Aberdeen Group plc boosted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 30.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 983,048 shares of the biotechnology company’s stock after purchasing an additional 227,773 shares during the quarter. Aberdeen Group plc owned 0.51% of BioMarin Pharmaceutical worth $54,038,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Dodge & Cox raised its stake in BioMarin Pharmaceutical by 1.4% in the 1st quarter. Dodge & Cox now owns 14,955,240 shares of the biotechnology company’s stock worth $1,057,186,000 after purchasing an additional 209,005 shares in the last quarter. AQR Capital Management LLC raised its stake in BioMarin Pharmaceutical by 127.9% in the 1st quarter. AQR Capital Management LLC now owns 2,925,805 shares of the biotechnology company’s stock worth $203,987,000 after purchasing an additional 1,642,206 shares in the last quarter. Nuveen LLC acquired a new stake in BioMarin Pharmaceutical in the 1st quarter worth about $184,475,000. Goldman Sachs Group Inc. raised its stake in BioMarin Pharmaceutical by 212.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company’s stock worth $112,607,000 after purchasing an additional 1,083,512 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in BioMarin Pharmaceutical by 7.6% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,532,314 shares of the biotechnology company’s stock worth $108,319,000 after purchasing an additional 108,806 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Guggenheim lifted their price objective on shares of BioMarin Pharmaceutical from $101.00 to $106.00 and gave the stock a “buy” rating in a research note on Wednesday, August 6th. Wedbush restated an “outperform” rating and issued a $94.00 target price on shares of BioMarin Pharmaceutical in a research report on Tuesday, August 5th. Weiss Ratings restated a “sell (d+)” rating on shares of BioMarin Pharmaceutical in a research report on Wednesday. Wolfe Research set a $95.00 target price on shares of BioMarin Pharmaceutical and gave the company an “outperform” rating in a research report on Tuesday, July 15th. Finally, JPMorgan Chase & Co. boosted their target price on shares of BioMarin Pharmaceutical from $116.00 to $119.00 and gave the company an “overweight” rating in a research report on Thursday. Thirteen analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, BioMarin Pharmaceutical has a consensus rating of “Moderate Buy” and an average target price of $93.26.

BioMarin Pharmaceutical Trading Down 2.8%

Shares of BioMarin Pharmaceutical stock opened at $52.32 on Friday. The firm has a market capitalization of $10.05 billion, a PE ratio of 15.53, a price-to-earnings-growth ratio of 0.66 and a beta of 0.33. The company has a current ratio of 5.56, a quick ratio of 3.60 and a debt-to-equity ratio of 0.10. The firm’s 50 day moving average is $56.37 and its 200 day moving average is $58.09. BioMarin Pharmaceutical Inc. has a 1 year low of $51.78 and a 1 year high of $73.51.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.